COMPANY

BioKier Inc.

Also known as BioKier · 4 sources

Keywords: diabetes mellitus metabolic Type 2 Diabetes Hypercholesterolemia Type 2 Diabetes Mellitus BKR-017

Profile checked Oct 10, 2026

Timeline

Jul 16, 2025 Trial start —: Pharmacokinetics of Butyrate Tablet BKR-017 source ↗
Apr 18, 2021 Trial start Not phased (device or behavioral study): Dose-Response Study to Evaluate the Effect of BKR-017 on Insulin Resistance and Other Metabolic Parameters in Type 2 Diabetes Patients source ↗
Jun 16, 2020 Trial start Not phased (device or behavioral study): Effects of BKR-017 on Insulin Resistance in Type 2 Diabetes Patients source ↗
Jan 9, 2018 Trial start Not phased (device or behavioral study): Effect of BKR-013 on Average Daily Glucose Levels source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT06556745	Pharmacokinetics of Butyrate Tablet BKR-017	Not listed	Completed	Jul 16, 2025	May 6, 2026 (actual)
NCT04673656	Dose-Response Study to Evaluate the Effect of BKR-017 on Insulin Resistance and Other Metabolic Parameters in Type 2 Diabetes Patients	Not phased (device or behavioral study)	Completed	Apr 18, 2021	Dec 10, 2022 (actual)
NCT04279444	Effects of BKR-017 on Insulin Resistance in Type 2 Diabetes Patients	Not phased (device or behavioral study)	Completed	Jun 16, 2020	Nov 10, 2020 (actual)
NCT03382015	Effect of BKR-013 on Average Daily Glucose Levels	Not phased (device or behavioral study)	Completed	Jan 9, 2018	Jun 30, 2018 (actual)